These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24608973)

  • 21. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
    Jensen PB; Christensen IJ; Sehested M; Hansen HH; Vindeløv L
    Br J Cancer; 1993 Feb; 67(2):311-20. PubMed ID: 8094293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
    Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX
    Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anti-proliferation of human cervical cancer HeLa cell line by fascaplysin through apoptosis induction].
    Lu XL; Zheng YL; Chen HM; Yan XJ; Wang F; Xu WF
    Yao Xue Xue Bao; 2009 Sep; 44(9):980-6. PubMed ID: 20055172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo.
    Lin J; Yan XJ; Chen HM
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):439-45. PubMed ID: 16816972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autophagy represses fascaplysin-induced apoptosis and angiogenesis inhibition via ROS and p8 in vascular endothelia cells.
    Meng N; Mu X; Lv X; Wang L; Li N; Gong Y
    Biomed Pharmacother; 2019 Jun; 114():108866. PubMed ID: 30999113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.
    Mahgoub T; Eustace AJ; Collins DM; Walsh N; O'Donovan N; Crown J
    Int J Oncol; 2015 Sep; 47(3):900-8. PubMed ID: 26201960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells.
    Thompson R; Meuth M; Woll P; Zhu Y; Danson S
    Int J Oncol; 2012 Jan; 40(1):194-202. PubMed ID: 21894433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gallic acid induces apoptosis and enhances the anticancer effects of cisplatin in human small cell lung cancer H446 cell line via the ROS-dependent mitochondrial apoptotic pathway.
    Wang R; Ma L; Weng D; Yao J; Liu X; Jin F
    Oncol Rep; 2016 May; 35(5):3075-83. PubMed ID: 26987028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.
    Huang CH; Treat J
    Oncology; 2001; 61 Suppl 1():14-24. PubMed ID: 11598410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling.
    Shafiq MI; Steinbrecher T; Schmid R
    PLoS One; 2012; 7(8):e42612. PubMed ID: 22905154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fascaplysin Sensitizes Anti-Cancer Effects of Drugs Targeting AKT and AMPK.
    Oh TI; Lee JH; Kim S; Nam TJ; Kim YS; Kim BM; Yim WJ; Lim JH
    Molecules; 2017 Dec; 23(1):. PubMed ID: 29295560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fascaplysin Exerts Anti-Cancer Effects through the Downregulation of Survivin and HIF-1α and Inhibition of VEGFR2 and TRKA.
    Oh TI; Lee YM; Nam TJ; Ko YS; Mah S; Kim J; Kim Y; Reddy RH; Kim YJ; Hong S; Lim JH
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28961193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of the mechanism and apoptotic pathway induced by 4β cinnamido linked podophyllotoxins against human lung cancer cells A549.
    Kamal A; Nayak VL; Bagul C; Vishnuvardhan MV; Mallareddy A
    Apoptosis; 2015 Nov; 20(11):1518-29. PubMed ID: 26386574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
    van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
    Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
    Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
    Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
    Takigawa N; Takeyama M; Kozuki T; Shibayama T; Hisamoto A; Kiura K; Tada A; Hotta K; Umemura S; Ohashi K; Fujiwara Y; Takata S; Ichihara E; Osawa M; Tabata M; Tanimoto M; Takahashi K
    Oncol Rep; 2007 May; 17(5):983-7. PubMed ID: 17390033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
    Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B
    Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Total Syntheses and Preliminary Biological Evaluation of Brominated Fascaplysin and Reticulatine Alkaloids and Their Analogues.
    Zhidkov ME; Smirnova PA; Tryapkin OA; Kantemirov AV; Khudyakova YV; Malyarenko OS; Ermakova SP; Grigorchuk VP; Kaune M; Amsberg GV; Dyshlovoy SA
    Mar Drugs; 2019 Aug; 17(9):. PubMed ID: 31450717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin.
    Kaufmann SH; Kalemkerian GP; Jasti R; Mabry M
    Biochem Pharmacol; 1995 Dec; 50(12):1987-93. PubMed ID: 8849324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.